Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.87 (market cap $868.62M), while iShares Core MSCI Emerging Markets ETF trades at $81.22. The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | IEMG | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $86.00 |
52-Week Low | $16.87 | $61.76 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
IEMG trades at $81.10, up 1.93% with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% trailing returns but faces elevated volatility. Recent news highlights IEMG's 40% technology weighting and AI exposure in emerging markets, though some analysts caution about concentration risks after significant gains.
The outlook remains positive given attractive emerging market valuations and AI-driven growth potential, but investors should monitor volatility and geopolitical risks. The ETF's low 0.09% expense ratio and diversification across 2,700 stocks provide cost-effective exposure to developing economies with superior dividend growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
